Symbicort (Budesonide + Formoterol) Drug Analysis & Outlook 2017-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Symbicort” report has been added to ResearchAndMarkets.com’s offering.

AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting with approval for asthma. This was followed by approval for chronic obstructive pulmonary disease in the EU in 2003 and in the US in February 2009.

In Japan, where Symbicort is co-promoted by Astellas and AstraZeneca, the drug received approval in August 2012. Budesonide is an ICS that exhibits potent glucocorticoid activity, and formoterol is a LABA that acts locally in the lungs as a bronchodilator.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Symbicort: Chronic obstructive pulmonary disease (COPD)
  4. Symbicort: Asthma

List of Figures

Figure 1: Symbicort for COPD – SWOT analysis

Figure 2: The authors drug assessment summary of Symbicort for COPD

Figure 3: The authors drug assessment summary of Symbicort for COPD

Figure 4: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Symbicort for asthma – SWOT analysis

Figure 6: The authors drug assessment summary of Symbicort in asthma

Figure 7: The authors drug assessment summary of Symbicort in asthma

Figure 8: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Symbicort drug profile

Table 2: Overview of pivotal trial data for Symbicort in COPD

Table 3: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 4: Symbicort drug profile

Table 5: Symbicort pivotal trial data in asthma

Table 6: Symbicort late-phase trial data in asthma

Table 7: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/42h4g0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Respiratory Drugs